CL2012001304A1 - Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas. - Google Patents
Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.Info
- Publication number
- CL2012001304A1 CL2012001304A1 CL2012001304A CL2012001304A CL2012001304A1 CL 2012001304 A1 CL2012001304 A1 CL 2012001304A1 CL 2012001304 A CL2012001304 A CL 2012001304A CL 2012001304 A CL2012001304 A CL 2012001304A CL 2012001304 A1 CL2012001304 A1 CL 2012001304A1
- Authority
- CL
- Chile
- Prior art keywords
- antigen
- binds
- peptide
- antibody
- human
- Prior art date
Links
- 230000001154 acute effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000004154 complement system Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26469609P | 2009-11-26 | 2009-11-26 | |
EP09014745A EP2327725A1 (en) | 2009-11-26 | 2009-11-26 | Anti-C5a binding moieties with high blocking activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2012001304A1 true CL2012001304A1 (es) | 2012-08-03 |
Family
ID=41683202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2012001304A CL2012001304A1 (es) | 2009-11-26 | 2012-05-18 | Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas. |
Country Status (26)
Country | Link |
---|---|
US (4) | US8802096B2 (es) |
EP (4) | EP2327725A1 (es) |
JP (4) | JP6104605B2 (es) |
KR (3) | KR102112969B1 (es) |
CN (2) | CN102741283B (es) |
AU (1) | AU2010324141B2 (es) |
BR (1) | BR112012012514B1 (es) |
CA (1) | CA2780520C (es) |
CL (1) | CL2012001304A1 (es) |
CY (2) | CY1118463T1 (es) |
DK (2) | DK2504362T3 (es) |
EA (1) | EA022759B1 (es) |
ES (2) | ES2613352T3 (es) |
HR (2) | HRP20170041T1 (es) |
HU (2) | HUE032543T2 (es) |
IL (1) | IL219911A (es) |
LT (2) | LT2504362T (es) |
MX (1) | MX2012006060A (es) |
NZ (1) | NZ600348A (es) |
PE (1) | PE20130314A1 (es) |
PL (2) | PL3181582T3 (es) |
PT (2) | PT3181582T (es) |
RS (2) | RS55571B1 (es) |
SI (2) | SI3181582T1 (es) |
SM (1) | SMT201700054B (es) |
WO (1) | WO2011063980A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
SG189775A1 (en) | 2008-04-11 | 2013-05-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US8703129B2 (en) | 2008-09-07 | 2014-04-22 | GlycoNex, Inc. | Antibodies against extended type 1 chain antigens, derivatives thereof and use |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
MX340696B (es) | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anticuerpos anti-c5a y metodos para usar los anticuerpos. |
CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
AU2012272706B2 (en) | 2011-06-22 | 2017-07-06 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
SG11201404942UA (en) * | 2012-02-20 | 2014-09-26 | Swedish Orphan Biovitrum Ab Publ | Polypeptides binding to human complement c5 |
EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
SG11201602679VA (en) | 2013-08-28 | 2016-05-30 | Swedish Orphan Biovitrum Ab Publ | Stable polypeptides binding to human complement c5 |
RU2714156C2 (ru) | 2013-08-28 | 2020-02-12 | Аффибоди Аб | С5-связующие полипептиды |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
BR112016021629A2 (pt) * | 2014-03-20 | 2018-07-10 | Inflarx Gmbh | inibidores de c5a para o tratamento de pneumonia viral |
AU2015315396B2 (en) | 2014-09-09 | 2020-10-08 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
UA124143C2 (uk) | 2015-05-20 | 2021-07-28 | Янссен Байотек, Інк. | Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень |
CA2990406A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
SI3370770T1 (sl) | 2015-11-03 | 2021-03-31 | Janssen Biotech, Inc. | Subkutane formulacije protiteles proti CD38 in njihove uporabe |
CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
WO2017196960A1 (en) * | 2016-05-10 | 2017-11-16 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
AU2018230657A1 (en) * | 2017-03-06 | 2019-09-26 | The Trustees Of The University Of Pennsylvania | Anti-C5 antibodies and uses thereof |
SG11201908744PA (en) * | 2017-03-23 | 2019-10-30 | Univ Pennsylvania | Anti-c5a antibodies and uses thereof |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
EP3411400B1 (en) * | 2017-04-03 | 2021-09-22 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
SG11201912882QA (en) | 2017-06-23 | 2020-01-30 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
WO2021190770A1 (en) | 2020-03-27 | 2021-09-30 | Inflarx Gmbh | INHIBITORS OF C5A FOR THE TREATMENT OF CORONA VIRUS Infection |
TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗c5a抗體 |
AU2022207985A1 (en) | 2021-01-13 | 2023-07-06 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
WO2023050233A1 (en) * | 2021-09-29 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5a antibodies and uses thereof |
CN116670288A (zh) * | 2021-12-22 | 2023-08-29 | 舒泰神(北京)生物制药股份有限公司 | 一种分离的抗C5a抗体及其制剂与应用 |
CN117203230A (zh) * | 2022-04-02 | 2023-12-08 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别c5a的抗体及其应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6673346B1 (en) * | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
AU2002331601B2 (en) | 2001-08-17 | 2006-04-13 | Tanox, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
EP3372243A1 (en) * | 2001-08-17 | 2018-09-12 | Genentech, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
EP1499352A4 (en) * | 2002-04-12 | 2006-10-11 | Medimmune Inc | ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES |
EP2327725A1 (en) * | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
MX340696B (es) | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anticuerpos anti-c5a y metodos para usar los anticuerpos. |
-
2009
- 2009-11-26 EP EP09014745A patent/EP2327725A1/en not_active Withdrawn
-
2010
- 2010-11-26 DK DK10782561.4T patent/DK2504362T3/en active
- 2010-11-26 SI SI201031978T patent/SI3181582T1/sl unknown
- 2010-11-26 LT LTEP10782561.4T patent/LT2504362T/lt unknown
- 2010-11-26 JP JP2012540323A patent/JP6104605B2/ja active Active
- 2010-11-26 PL PL16199344T patent/PL3181582T3/pl unknown
- 2010-11-26 CN CN201080062363.8A patent/CN102741283B/zh active Active
- 2010-11-26 EP EP10782561.4A patent/EP2504362B1/en active Active
- 2010-11-26 KR KR1020197009756A patent/KR102112969B1/ko active IP Right Grant
- 2010-11-26 HU HUE10782561A patent/HUE032543T2/en unknown
- 2010-11-26 MX MX2012006060A patent/MX2012006060A/es active IP Right Grant
- 2010-11-26 LT LTEP16199344.9T patent/LT3181582T/lt unknown
- 2010-11-26 HU HUE16199344A patent/HUE049376T2/hu unknown
- 2010-11-26 ES ES10782561.4T patent/ES2613352T3/es active Active
- 2010-11-26 WO PCT/EP2010/007197 patent/WO2011063980A1/en active Application Filing
- 2010-11-26 CN CN201510333262.4A patent/CN105037541A/zh active Pending
- 2010-11-26 US US13/512,334 patent/US8802096B2/en active Active
- 2010-11-26 RS RS20170025A patent/RS55571B1/sr unknown
- 2010-11-26 BR BR112012012514-1A patent/BR112012012514B1/pt active IP Right Grant
- 2010-11-26 KR KR1020127016454A patent/KR101844611B1/ko active IP Right Grant
- 2010-11-26 CA CA2780520A patent/CA2780520C/en active Active
- 2010-11-26 RS RS20200194A patent/RS59955B1/sr unknown
- 2010-11-26 PE PE2012000715A patent/PE20130314A1/es active IP Right Grant
- 2010-11-26 PL PL10782561T patent/PL2504362T3/pl unknown
- 2010-11-26 SI SI201031368A patent/SI2504362T1/sl unknown
- 2010-11-26 EP EP16199344.9A patent/EP3181582B1/en active Active
- 2010-11-26 DK DK16199344.9T patent/DK3181582T3/da active
- 2010-11-26 AU AU2010324141A patent/AU2010324141B2/en active Active
- 2010-11-26 NZ NZ600348A patent/NZ600348A/en unknown
- 2010-11-26 PT PT161993449T patent/PT3181582T/pt unknown
- 2010-11-26 PT PT107825614T patent/PT2504362T/pt unknown
- 2010-11-26 EP EP20153768.5A patent/EP3670532A1/en not_active Withdrawn
- 2010-11-26 KR KR1020187008236A patent/KR20180034690A/ko active Application Filing
- 2010-11-26 EA EA201200795A patent/EA022759B1/ru unknown
- 2010-11-26 ES ES16199344T patent/ES2773725T3/es active Active
-
2012
- 2012-05-18 CL CL2012001304A patent/CL2012001304A1/es unknown
- 2012-05-21 IL IL219911A patent/IL219911A/en active IP Right Grant
-
2014
- 2014-06-27 US US14/317,968 patent/US9073983B2/en active Active
-
2015
- 2015-06-03 US US14/729,865 patent/US9458233B2/en active Active
- 2015-12-02 JP JP2015235562A patent/JP6591272B2/ja active Active
-
2016
- 2016-09-16 US US15/267,902 patent/US10774136B2/en active Active
-
2017
- 2017-01-11 HR HRP20170041TT patent/HRP20170041T1/hr unknown
- 2017-01-12 CY CY20171100048T patent/CY1118463T1/el unknown
- 2017-01-24 SM SM201700054T patent/SMT201700054B/it unknown
- 2017-11-27 JP JP2017226849A patent/JP2018080170A/ja active Pending
-
2019
- 2019-04-16 JP JP2019077667A patent/JP2019163266A/ja active Pending
-
2020
- 2020-02-12 HR HRP20200241TT patent/HRP20200241T1/hr unknown
- 2020-02-19 CY CY20201100151T patent/CY1122674T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2012001304A1 (es) | Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas. | |
CL2013000390A1 (es) | Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer. | |
CL2014002750A1 (es) | Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer | |
CL2014000590A1 (es) | Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. | |
CL2012002896A1 (es) | Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva. | |
CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
CL2013002811A1 (es) | Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion. | |
CL2013000843A1 (es) | Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso. | |
CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
CL2014000758A1 (es) | Anticuerpo aislado o fragmento del mismo que se une especificamente a erbb3; composicion farmaceutica que lo comprende; y su uso para inhibir el crecimiento tumoral. | |
CL2008002952A1 (es) | Proteina de union a antigenos que se une a interleucina-23 humana (il-23); composicion farmaceutica que la comprende; y su uso para tratar inflamaciones mediadas por el sistema inmunitario | |
BR112013017080A8 (pt) | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente | |
UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
BR112012022210A2 (pt) | anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado | |
JP2014043446A5 (es) | ||
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
CL2011002877A1 (es) | Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer. | |
CL2013000097A1 (es) | Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal. | |
BR112014002608A2 (pt) | anticorpo ou seu fragmento que possui reatividade imunológica com um polipeptídeo caprin-1, composição farmacêutica e combinação farmacêutica de tratamento e/ou prevenção de câncer, dna e método de tratamento e/ou prevenção de câncer | |
IL212633A (en) | A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs | |
CL2008000887A1 (es) | Compuestos derivados de 3-hidroxi-1h-pirimidin-4-ona o 3-hidroxi-piran-4-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad neurodegenerativa causada por la presencia de | |
CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
CL2012002438A1 (es) | Anticuerpo aislado que se une a peptido ciclico derivado de peptido betaamiloide (ab); inmunoconjugado que comprende dicho anticuerpo; metodo para tratar o prevenir enfermedad de alzheimer que comprende el anticuerpo antes mencionado; kit que comprende el anticuerpo. | |
EA201690159A1 (ru) | Способы и композиции для лечения рака |